• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Avatrombopag Maleate
BioHub® Magnetic Separator
Avatrombopag
Ursodeoxycholic acid
Troxerutin
CytoLinX® BRTF Single-use Top-driven Bioreactor Bag

Chilean Sinovac trial leaders recommend third dose of COVID-19 vaccine

firstwordpharmaJuly 16, 2021

Tag: COVID-19 , Vaccine , CoronaVac

The leaders of Chile’s late-stage human trial of Sinovac’s COVID-19 vaccine CoronaVac recommended a third dose of the shot, saying studies of participants showed their protecting antibody levels were lower after six months, as reported by Yahoo!News on Thursday.

Chilean Sinovac trial leaders recommend third dose of COVID-19 vaccine

According to the leaders, an in vitro trial to determine the shot’s effectiveness against the Delta variant of the virus showed a four-fold reduction in neutralizing effect against it, compared to a less severe, three-fold reduction previously reported by scientists in China.


Previous:TrippBio receives Notice of Allowance from the U.S. Patent Office for Therapeutic Treatment of COVID-19 Infections

Next:Corvus Pharmaceuticals Discontinues Phase 3 Study of Mupadolimab (Anti-CD73) for COVID-19 Due to Vaccine Effectiveness in Reducing Hospitalizations

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

Chilean Sinovac trial leaders recommend third dose of COVID-19 vaccine | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

You may like
More>>

High-standard and high quality Influenza Vaccine (Split virion), inactivated

High-standard and high quality Influenza Vaccine (Split virion), inactivated
Group ACYW135 Meningococcal Polysaccharide Vaccine with lower side effect

Group ACYW135 Meningococcal Polysaccharide Vaccine with lower side effect
Hualan Biological Recombinant Hepatitis B Vaccine (Hansenula polymorpha)with Excellent bacteria stra

Hualan Biological Recombinant Hepatitis B Vaccine (Hansenula polymorpha)with Excellent bacteria stra
Poultry Vaccine Series

Poultry Vaccine Series
Quadrivalent Influenza Vaccine in 2022

Quadrivalent Influenza Vaccine in 2022
Animal Vaccine Filling Line

Animal Vaccine Filling Line
Quadrivalent Influenza Vaccine, Inactivated of Hualan

Quadrivalent Influenza Vaccine, Inactivated of Hualan
Poliomyelitis Vaccine Type I Type III in Dragee Candy (Human Diploid Cell), Live

Poliomyelitis Vaccine Type I Type III in Dragee Candy (Human Diploid Cell), Live
Recommended flu vaccine 2023-2024 by WHO

Recommended flu vaccine 2023-2024 by WHO
Hualan's Influenza Vaccine

Hualan's Influenza Vaccine

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service